NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.
 
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO ACQUIRE ANY SECURITIES. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
 
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (“MAR”) AND ARTICLE 7 OF MAR AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”).

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON, “Faron” or the “Company”) announced on 9 February 2026 that it is planning a share issue with pre-emptive subscription rights for the Company’s existing shareholders.

Based on an authorisation granted by the Extraordinary General Meeting on 2 March 2026 and by the Annual General Meeting of Shareholders of the Company on 21 March 2025, Faron today publishes the terms and conditions of a fully committed and guaranteed rights offering of approximately EUR 40 million with a subscription price of EUR 0.50 per offer share (the “Offering”). The purpose of the Offering is to strengthen the Company’s financial position, to run a randomized, 90-patient Phase II trial in frontline high risk myelodysplastic syndrome (“HR MDS”) with bexmarilimab in combination with azacitidine as well as to accelerate the development of its lead asset bexmarilimab by providing it to up to five investigator-initiated trials (“IIT”).

The Company has received subscription commitments and cornerstone commitments of EUR 11.76 million in total, including from long-term shareholder Blood Cancer United Therapy Acceleration Program® (TAP). With the confirmed gross proceeds of approximately EUR 40 million the Company extends its runway until November 2027. On the date of this announcement the Company has working capital until mid-April 2026.

The Offering in brief:

• An Offering of up to 80,158,126 offer shares (the “Offer Shares”) which may be represented by depository interests (“DIs”) (“Offer DIs”) to raise approximately EUR 40 million.
• As a result of the Offering, the total number of shares in the Company may, upon completion, increase from 119,472,660 shares to a maximum of 199,472,660 shares. Assuming that the Offering is fully subscribed for, the Offer Shares would represent approximately 67.1 per cent of the existing shares in the Company.
• Shareholders who are registered in the Company’s shareholder register on the Record Date will receive one Subscription Right (as defined below) for each existing share of the Company.
• 13 Subscription Rights will entitle the holder to subscribe for 9 Offer Shares or Offer DIs at a EUR 0.5 subscription price per Offer Share or Offer DI (the “Subscription Price”).
• The Subscription Price represents a discount of 7.54% to the theoretical ex-rights price based on the closing price of EUR 0.569 on Nasdaq Helsinki on 9 March 2026.
• The Company has received subscription commitments and cornerstone commitments of EUR 11.76 million in total, including from long-term shareholder Blood Cancer United Therapy Acceleration Program® (TAP).
• Further, certain investors have agreed to subscribe for any Offer Shares not otherwise subscribed and paid for pursuant to the Subscription Rights or in the secondary subscription for an aggregate amount of up to EUR 28.32 million, subject to certain conditions.
• In the aggregate, the received Commitments (as defined below) represent approximately 100 per cent of the Offer Shares.
• The record date for the Offering is 12 March 2026 (the “Record Date”).
• The Subscription Rights will be subject to trading on Nasdaq First North Growth Market Finland (“First North”) and in the form of DIs on AIM (“AIM”), the market of that name operated by London Stock Exchange plc (the “LSE”), between 17 March 2026 and 27 March 2026.
• DI Subscription Period on AIM: from 17 March 2026 to 31 March 2026.
• Share Subscription Period on First North: from 17 March 2026 to 2 April 2026.

Dr. Juho Jalkanen, CEO of Faron, comments:

“There is a persistent and profound need for new treatments in HR MDS,. Our data from the open-label BEXMAB Phase I/II trial and recent developments in the field of HR MDS has put us in a leading position in this field. With this raise we aim to deliver a randomized placebo-controlled Phase IIb data set for regulatory and business purposes. We wish to thank all existing and new investors already committing to this round and making it a success. It gives us now great pleasure to open this offering also to the public with first rights to subscribe to our existing shareholders. Truly exciting times ahead with additional data being generated in up to five new cancers, possibly showing the broader potential we believe bexmarilimab has by overcoming treatment resistance caused by macrophages, not just in HR MDS, but in several cancers.”

“We are pleased to continue our partnership with Faron through this additional investment as they progress bexmarilimab toward its next phase of clinical development,” said Blaine Robinson, PhD, Vice President, Blood Cancer United Therapy Acceleration Program® (TAP). “There remains a critical need for new treatments for patients with blood cancers, and TAP is designed to accelerate the most promising treatments with the potential to transform outcomes. Innovative immune-activating combinations like those being explored by Faron hold significant promise because they aim not only to target the cancer directly but also to activate a broader, durable immune response.”

General:

• Faron aims to issue up to 80,158,126 Offer Shares for subscription in the Offering to raise gross proceeds of approximately EUR 40 million.
• 13 Subscription Rights will entitle the holder to subscribe for 9 Offer Shares or Offer DIs
• The Subscription Price for each Offer Share is EUR 0.50.
• The Subscription Price represents a discount of 7.54% to the theoretical ex-rights price based on the closing price of EUR 0.569 on Nasdaq Helsinki on 9 March 2026.
• The Subscription Price will be recorded in the reserve for invested unrestricted equity of the Company.
• The Record Date for the Offering is 12 March 2026.
• The existing shareholders of Faron have a pre-emptive right to subscribe for Offer Shares (the “Subscription Right”) issued in the Offering in proportion to their existing shareholdings in Faron.
• Shareholders who are registered in the Company’s shareholder register maintained by Euroclear Finland Oy (“Euroclear Finland”) on the Record Date will receive one (1) Subscription Right for each existing share of the Company (“Existing Shares”) held on the Record Date.
• The Company’s DI holders (“DI Shareholders”) who are registered in the Company’s DI register maintained by Computershare Investor Services Plc on the Record Date will receive one (1) Subscription Right for each DI held on the Record Date.
• The Subscription Rights granted in the Offering will be recorded on shareholders’ book-entry accounts on 13 March 2026.The Subscription Rights are freely transferable, and they are subject to trading on First North maintained by Nasdaq Helsinki Ltd under the trading code “FARONU0126” (ISIN code: FI4000602313) between 17 March 2026 and 27 March 2026 and in the form of DIs on AIM under the trading code “FARONU0126 ” (ISIN code: FI4000602313), the market of that name operated by London Stock Exchange plc (the “LSE”) between 17 March 2026 and 27 March 2026.
• The Company has, prior to the Offering, received commitments for an aggregate amount of up to EUR 4.71 million from certain of its existing shareholders to subscribe for Offer Shares in the Offering with all or part of the Subscription Rights granted. In addition, certain investors have agreed to subscribe for Offer Shares that have not been subscribed for in the Offering pursuant to the Subscription Rights for an aggregate amount of up to EUR 7.05 million. Further, certain investors have agreed to subscribe for any Offer Shares not otherwise subscribed and paid for pursuant to the Subscription Rights or in the secondary subscription for an aggregate amount of up to EUR 28.32 million (together the “Commitments”).
• In the aggregate, the Commitments represent approximately 100 per cent of the Offer Shares.
• The subscription period for the Offer Shares will commence on 17 March 2026 at 10:00 a.m. and expire on 2 April 2026 at 4:30 p.m. (Finnish time).
• The subscription period for the Offer DIs will commence on 17 March 2026 at 8:00 a.m. and expire on 31 March 2026 at 11:00 a.m. (London time).
• Faron will publish a Finnish language prospectus regarding the Offering approved by the Finnish Financial Supervisory Authority on or about 11 March 2026 before the subscription period commences.
• Separately from the Offering, the Company may also carry out directed share issues of up to a total of 19,296,473 million shares at a subscription price that will be at least equal to the Subscription Price in the Offering.
• Stifel Europe Securities SAS is acting as the sole global coordinator of the Offering (the “Sole Global Coordinator”).
• The terms and conditions of the Offering are attached to this release as Appendix 1.

Commitments

The Company has, prior to the Offering, received commitments for an aggregate amount of up to EUR 4.71 million from certain of its existing shareholders including Blood Cancer United Therapy Acceleration Program® (TAP) to subscribe for Offer Shares in the Offering with all or part of the Subscription Rights granted for them. Such subscription commitments are binding, irrevocable and subject to the fulfilment of certain customary conditions.

In addition, certain investors have agreed to subscribe for Offer Shares that have not been subscribed for in the Offering pursuant to the Subscription Rights for an aggregate amount of up to EUR 7.05 million. Such cornerstone commitments are binding, irrevocable and subject to the fulfilment of certain customary conditions.

Further, certain investors have agreed to subscribe for any Offer Shares not otherwise subscribed and paid for pursuant to the Subscription Rights or in the secondary subscription for an aggregate amount of up to EUR 28.32 million. Such subscription guarantees are binding, irrevocable and subject to the fulfilment of certain customary conditions. Heights Capital Management’s subscription guarantee is also subject the Company having executed certain amendments to the terms of its bond instruments of which Heights Capital Management is a holder of, and a material adverse effect provision, and that subscription guarantees from other investors remain in force.

In the aggregate, these Commitments represent approximately 100 per cent of the Offer Shares.

Important Dates for the Offering

• 10 March 2026 Last day of trading in the shares with a right to Subscription Rights
• 11 March 2026 First day of trading in the shares excluding a right to Subscription Rights
• 12 March 2026 Record Date of the Offering
• 13 March 2026 The Subscription Rights are recorded on shareholders’ book-entry accounts
• 17 March 2026 Share Subscription Period and Right Trading Period on First North will commence
• 17 March 2026 DI Subscription Period and Right Trading Period on AIM
• 27 March 2026 DI Right Trading Period on AIM expires
• 27 March 2026 Right Trading Period on First North expires
• 30 March 2026 Suspension of trading in Subscription Rights on AIM (from 7:30 a.m.)
• 31 March 2026 Share Subscription Period on AIM expires
• 2 April 2026 Share Subscription Period on First North expires
• 8 April 2026 Preliminary result of the Offering are announced
• 9 April 2026 Final results of the Offering are announced
• 14 April 2026 Trading in interim shares ends on First North
• 14 April 2026 Trading in DIs representing interim shares ends on AIM
• 14 April 2026 Registration of new Offer Shares
• 15 April 2026 Listing of and start of trading in the new Offer Shares on First North and in the Offer DIs on AIM

Background for the Offering:

The Company has reached a critical stage in the advancement of bexmarilimab. In order to position the Company to achieve the next expected key value-inflection milestones, Faron’s Board of Directors has undertaken a detailed review of the development plan of bexmarilimab and forecasted funding requirements. With the proposed Offering the Company aims to fund the randomized Phase II trial of bexmarilimab in combination with azacitidine in frontline high risk myelodysplastic syndrome (HR MDS) along with supporting several investigator‑initiated combination trials across multiple cancers.

Use of Proceeds:

The Company aims to raise through the Offering total gross proceeds of EUR 40 million, and net proceeds of approximately EUR 32.8 million. The net proceeds of the Offering are mainly intended to be used to finance the randomized, 90-patient Phase II trial with bexmarilimab in combination with azacitidine in frontline HR MDS until the following major milestones: i) completion of the complete response rate readout (CR); ii) determination of the recommended Phase III dose (RP3D); iii) FDA meeting for CR as the approval endpoint; and iv) potential request for Accelerated Approval in last line MDS (r/r MDS). Additionally, net proceeds are intended to be used to support up to five investigator-initiated trials to further validate bexmarilimab’s potential in combination trials in melanoma, non-small cell lung carcinoma, soft tissue sarcoma, breast cancer (ER+ BRC), r/r MDS and acute myeloid leukaemia as well as for working capital and general corporate purposes. According to the Company’s estimate, net proceeds of EUR 32.8 million would be sufficient for all of the above-mentioned main purposes.

Availability of the prospectus and terms and conditions of the Offering

The Company has prepared a Finnish language prospectus regarding the Offering (the “Prospectus”), which the Company expects to be approved by the Finnish Financial Supervisory Authority on or about 11 March 2026. Provided, that the Finnish Financial Supervisory approves the Prospectus, it will be available on Faron’s website at https://faron.fi/merkintaoikeusanti-2026 on or about 11 March 2026 before the Subscription Period commences. An English-language offering circular prepared by the Company regarding the Offering is expected to be available on the Company’s website at https://faron.com/rights-offering-2026 on or about 11 March 2026.

The detailed terms and conditions of the Offering are attached to this release as Appendix 1.

Directed Share Issues

Separately from the Offering, the Company may also carry out directed share issue of up to around 19 million shares (the “Directed Issue Shares”), the maximum number of shares that may be issued on the date of this company announcement under the authorisation granted by the Annual General Meeting of Shareholders (AGM) held on 21 March 2025, at a subscription price that will be at least equal to the subscription price in the Offering (the “Directed Share Issue”). The successful completion of the Directed Share Issue would strengthen the Company’s financial position.

The Company has entered into cornerstone commitments with certain investors (the “Cornerstone Investors”), raising aggregate proceeds of EUR 7.05 million. To the extent that Cornerstone Investors are not allocated Offer Shares, or are allocated Offer Shares in an amount less than the amount of their respective commitments, the Cornerstone Investors have further undertaken to subscribe for such a number of Directed Issue Shares in the Directed Share Issue which corresponds to the difference between the maximum amount under the respective commitment and the aggregate subscription price of Offer Shares allocated to the Cornerstone Investors of the Offering. The cornerstone commitments are binding and irrevocable and subject to the fulfilment of certain customary conditions.

Sole Global Coordinator and Bookrunner

The Company has appointed Stifel Europe Securities SAS as Sole Global Coordinator and Bookrunner of the Offering.

Offering webcast

The Company will host a virtual offering webcast on Tuesday, 17 March 2026. The offering webcast will be held in Finnish and English. The Finnish-language webcast starts at 5pm EET, and the English-language webcast starts at 6pm EET. During the event, Faron’s Chief Executive Officer, Dr. Juho Jalkanen and other members of Faron’s management team will provide an update on the Company’s development plans and the rationale behind the Offering.

Finnish-language offering webcast registration link

English-language offering webcast registration link

For the purposes of MAR and UK MAR, the person responsible for arranging for the release of this
announcement on behalf of the Company is Juho Jalkanen, Chief Executive Officer.

Faron Pharmaceuticals Ltd

For more information please contact:

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Important notice
This announcement is not an offer of securities for sale into the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act“), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in or into or from the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. There is no intention to register the securities in the United States or to make a public offering in the United States. Any sale of the securities in the United States will be made solely to a limited number of “qualified institutional buyers” as defined in Rule 144A in reliance on an exemption from the registration requirements of the Securities Act.

The distribution of this announcement may be restricted by law and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such relevant legal restrictions. The information contained herein is not for publication, distribution or release, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or the Republic of South Africa or any other jurisdiction in which the distribution, publication or release would be unlawful. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such aforementioned jurisdiction. This announcement is not directed to, and is not intended for distribution to or use by, any person or entity that is a citizen, resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would violate law or regulation or which would require any registration or licensing within such jurisdiction.

In any EEA Member State, other than Finland, this release is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of Article 2(e) of Regulation (EU) 2017/1129 (the “Prospectus Regulation“).

In the United Kingdom, this announcement is only directed at (a) members of the Company; and (b) “qualified investors” within the meaning of paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024 (the “POATR“) who are also (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); (ii) persons who fall within Article 49(2)(a) to (d) of the Order; or (iii) other persons to whom it may otherwise be lawfully communicated (all such persons together being “Relevant Persons“). This announcement must not be acted on or relied on in the United Kingdom by persons who are not Relevant Persons. Persons distributing this announcement must satisfy themselves that it is lawful to do so. Any investment or investment activity to which this announcement relates is only available to Relevant Persons in the United Kingdom and will only be engaged in with such persons.

In the United Kingdom, no prospectus, offering memorandum, offering document or admission document has been or will be made available in connection with the matters contained or referred to in this announcement and no such document is required to be published (in accordance with the POATR or the AIM Rules of the London Stock Exchange). This announcement has not been approved by the Financial Conduct Authority (the “FCA“) or the London Stock Exchange.

No part of this announcement, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The information contained in this release has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The Company or any of its respective affiliates, advisors or representatives or any other person, shall have no liability whatsoever (in negligence or otherwise) for any loss, however arising from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of the Company, its subsidiaries, its securities and the transactions, including the merits and risks involved.

The Sole Global Coordinator and Bookrunner is acting exclusively for the Company and no one else in connection with the Offering. It will not regard any other person as their respective client in relation to the Offering. It will not be responsible to anyone other than the Company for providing the duties afforded to its respective clients, nor for giving advice in relation to the Offering or any transaction or arrangement referred to herein.

Caution regarding forward-looking statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Company’s current expectations and assumptions regarding the completion and use of proceeds from the Offering, the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Company’s current beliefs and assumptions and are based on information currently available to the Company.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Company believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

Appendix 1 – Terms and conditions of the Offering

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, has, as announced earlier today on 3 February 2026, approved the exercise of 909,517 Special Rights entitling to 909,517 new Shares, for an aggregate subscription price of EUR 1,549,998.87.

In total 909,517 new shares in the Company have today on 3 February 2026 been registered in the Finnish Trade Register. The shares rank pari passu in all respects with the existing shares of the Company. Following the issuance, the aggregate number of ordinary shares in the Company is 119,472,660. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company continues to have 3,688,699 shares in treasury and therefore, the total number of voting rights in Faron is 115,783,961 (the “Number of Shares and Votes”). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

Trading in the new shares is expected to commence on First North and AIM on or around 5 February 2026.

For more information, please contact:

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). On 11 December 2025 the Company announced that it had resolved upon the issuance of a second tranche of convertible bonds amounting to EUR 10 million (the “Second Tranche Bonds”) due 2 December 2028, to HCM, convertible into new and/or existing Shares in the Company. As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds and the Second Tranche Bonds.

The Company has received a scheduled amortised payment notice from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 945,000 for First Tranche bonds and EUR 605,000 for Second Tranche Bonds. Therefore, total aggregate amortised payment amount (including accrued interest) is EUR 1,550,000. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 1.7042 per Share, corresponding to 90 per cent of the lowest of (i) the volume weighted average price (“VWAP”) of a Share on the relevant payment date, and (ii) the lowest of the VWAPs of a Share on each of the five consecutive dealing days ending on (and including) the dealing day immediately preceding the relevant payment date. Therefore, the Company has approved the exercise of 909,517 Special Rights entitling to 909,517 new Shares in total, for an aggregate subscription price of EUR 1,549,998.87. Of those Shares 554,512 are used to amortize the First Tranche Bonds (including accrued interest) and 355,005 the Second Trance Bonds (including accrued interest). The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and recorded into the reserve for invested unrestricted equity.

Admission and Total Voting Rights
The 909,517 Shares subscribed for and issued are expected to be registered in the Finnish Trade Register on or around 3 February 2026. The Shares will rank pari passu in all respects with the existing shares of the Company once they are registered with the Finnish Trade Register.

The Company will make applications for the admission of the newly issued Shares to trading on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“) with said admissions expected to become effective and trading to commence on or around 5 February 2026 (the “Admissions”).

Following the issuance, the aggregate number of ordinary shares in the Company is 119,472,660. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company will continue to have 3,688,699 shares in treasury (issued by the Company to itself previously on 27 May 2025) and therefore, the total number of voting rights in Faron will be 115,783,961 (the “Number of Shares and Votes“). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

For more information, please contact:

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). On 11 December 2025 the Company has resolved upon the issuance of EUR 10 million of Second Tranche Bonds, due 2 December 2028, to HCM, convertible into new and/or existing Shares in the Company. HCM (or any future holders of the majority of the First Tranche Bonds) may, at any time between scheduled amortisations, exercise their right to bring forward up to two (2) additional amortisation payments (an “Accelerated Amortisation”) of the First Tranche Bonds to be paid in advance, with a limit of no more than nine (9) Accelerated Amortisations in the first year of the term of the First Tranche Bonds. As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds.

The Company has on 8 January 2026 received an amortised payment advancement notice related to First Tranche Bonds from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 846,943.22. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 1.8656 per Share, corresponding to 90 per cent of the lowest of (i) the volume weighted average price (“VWAP”) of a Share on the relevant payment date, and (ii) the lowest of the VWAPs of a Share on each of the five consecutive dealing days ending on (and including) the dealing day immediately preceding the relevant payment date. Therefore, the Company has approved the exercise of 453,979 Special Rights entitling to 453,979 existing treasury Shares, for an aggregate subscription of EUR 846,943.22. The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and recorded into the reserve for invested unrestricted equity. The new Maturity Date of the Bond is 2 August 2027.

The 453,979 Shares subscribed for rank pari passu in all respects with the existing shares of the Company and are admitted to trading on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“).

Following the issuance, the aggregate number of ordinary shares in issue in the Company remains 118,563,143. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the issuance, the Company will have 3,688,699 shares in treasury and therefore, the total number of voting rights in Faron will be 114,874,444 (the “Number of Shares and Votes“). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

For more information, please contact:

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, has, as announced earlier today on 3 December 2025, approved the exercise of 517,795 Special Rights entitling to 517,795 new Shares, for an aggregate subscription price of EUR 965,998.35.

In total 517,795 new shares in the Company have today on 3 December 2025 been registered in the Finnish Trade Register. The shares rank pari passu in all respects with the existing shares of the Company. Following the issuance, the aggregate number of ordinary shares in the Company is 118,563,143. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company continues to have 4,142,678 shares in treasury and therefore, the total number of voting rights in Faron is 114,420,465 (the “Number of Shares and Votes”). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

Trading in the new shares is expected to commence on First North and AIM on or around 5 December 2025.

For more information, please contact:

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds.

The Company has received a scheduled amortised payment notice from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 966,000. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 1.8656 per Share, corresponding to 90 per cent of the lowest of (i) the volume weighted average price (“VWAP”) of a Share on the relevant payment date, and (ii) the lowest of the VWAPs of a Share on each of the five consecutive dealing days ending on (and including) the dealing day immediately preceding the relevant payment date. Therefore, the Company has approved the exercise of 517,795 Special Rights entitling to 517,795 new Shares, for an aggregate subscription price of EUR 965,998.35. The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and recorded into the reserve for invested unrestricted equity.

Admission and Total Voting Rights
The 517,795 Shares subscribed for and issued are expected to be registered in the Finnish Trade Register on or around 3 December 2025. The Shares will rank pari passu in all respects with the existing shares of the Company once they are registered with the Finnish Trade Register.

The Company will make applications for the admission of the newly issued Shares to trading on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“) with said admissions expected to become effective and trading to commence on or around 5 December 2025 (the “Admissions”).

Following the issuance, the aggregate number of ordinary shares in the Company is 118,563,143. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company will continue to have 4,142,678 shares in treasury (issued by the Company to itself previously on 27 May 2025) and therefore, the total number of voting rights in Faron will be 114,420,465 (the “Number of Shares and Votes“). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

For more information, please contact:

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

The Company announced on 3 April 2025 that it had entered into a convertible bond arrangement for up to EUR 35 million with an entity managed by Heights Capital Management, Inc. (“HCM”) and resolved upon the issuance of amortising senior unsecured convertible bonds with an aggregated principal amount of EUR 15 million (the “First Tranche Bonds”) due 2 April 2028 to HCM, convertible into new and/or existing shares in the Company (the “Shares”). HCM (or any future holders of the majority of the First Tranche Bonds) may, at any time between scheduled amortisations, exercise their right to bring forward up to two (2) additional amortisation payments (an “Accelerated Amortisation”) to be paid in advance, with a limit of no more than nine (9) Accelerated Amortisations in the first year of the term of the First Tranche Bonds. As previously announced, the Board of Directors of Faron has resolved to make amortisations and interest payments by converting the relevant amounts due into Shares (“Share Settlement Option”), unless it separately decides to make payments in cash. The exercise of the Company’s Share Settlement Option is effected by the bondholders exercising special rights entitling into Shares, as referred to in Chapter 10 of the Finnish Companies Act (“Special Rights”), issued in connection with the issuance of the First Tranche Bonds.

The Company has on 27 October 2025 received an amortised payment advancement notice from the bondholder for an aggregate amortised payment amount (including accrued interest) of EUR 844,647. As the Company has exercised its Share Settlement Option, the subscription price for the Shares subscribed for by the bondholder is EUR 1.8695 per Share, corresponding to the rate used in the Scheduled Amortisation on 2 October 2025. Therefore, the Company has approved the exercise of 451,803 Special Rights entitling to 451,803 new Shares, for an aggregate subscription price of EUR 844,645.71. The subscription price for the Shares subscribed for pursuant to the Special Rights is paid by setting off the Company’s debt to pay relevant amounts due under the First Tranche Bonds and recorded into the reserve for invested unrestricted equity. The new Maturity Date of the Bond is 2 October 2027.

Admission and Total Voting Rights
The 451,803 Shares subscribed for rank pari passu in all respects with the existing shares of the Company and are admitted to trading on Nasdaq First North Growth Market Finland (“First North“) maintained by Nasdaq Helsinki Ltd (“Nasdaq Helsinki“) and on AIM (“AIM“), the market of that name operated by London Stock Exchange plc (the “LSE“).

Following the issuance, the aggregate number of ordinary shares in the Company will be 118,045,348. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the issuance, the Company will continue to have 4,142,678 shares in treasury (issued by the Company to itself previously on 27 May 2025) and therefore, the total number of voting rights in Faron will be 113,902,670 (the “Number of Shares and Votes“). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

For more information, please contact:

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.